Table 1.
The basic characteristics of the eligible studies
| First author | Country | Age | Stage | Antibodies | Positivity (IHC) | Control groups | Cancer | Control | GS (≥ 7) | GS (≤ 6) | T stage 3–4 | T stage 1–2 | Lymph node metastasis (Yes) | Lymph node metastasis (No) | Bone metastasis (Yes) | Bone metastasis (No) | Clinical outcome-MA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | N (%) | E+/N | E+/N | E+/N | E+/N | E+/N | E+/N | E+/N | E+/N | ||||||||
| Went 2006 [36] | Switzerland | NA | T1-T4 | ESA, clone VU-1D9, Novocastra, Newcastle upon Tyne, UK, dilution 1: 50 | > 70% | 414 (87.2%) | 138/168 | 223/246 | 82/89 | 276/321 | 8/10 | 329/378 | No | ||||
| Mukherjee 2009 [35] | USA | NA | NA | Abcam, cat. #11294, dilution 1:200 | ≥ 20% | Normal | 23 (91.3%) | 20 (0%) | No | ||||||||
| Benko 2013 [23] | Croatia | 65 | T2-T3 | ab32392, ABCAM, Cambridge, MA, dilution 1:600 | ≥ 40% | Benign | 102 (52%) | 102 (1%) | Yes | ||||||||
| Ni 2013 [22] | Australia | NA | NA | Epitomics, Inc.dilution 1:100 | ≥ 25% | Benign | 10 (100%) | 10 (90%) | No | ||||||||
| Ni 2013 [22] | Australia | NA | NA | Epitomics, Inc.dilution 1:100 | ≥ 25% | Normal | 10 (100%) | 10 (20%) | No | ||||||||
| Rybalov 2014 [34] | The Netherlands | NA | T2-T4 | Clone VU-1D9, Leica Biosystems, Newcastle, UK, dilution 1:100 | Weak-strong | 17 (82.4%) | 11/14 | 2/2 | 11/14 | 3/3 | No | ||||||
| Li 2015 [27] | China | NA | NA | NA | 1–9 scores | Benign | 63 (88.9%) | 58 (0%) | 20/20 | 2/5 | No | ||||||
| Campos 2016 [32] | Mexico | NA | NA | clone VU-1D9, Leica Biosystems, Newcastle, UK, dilution 1:100 | TIS ≥ 1 | 42 (50%) | 21/21 | 0/21 | 19/20 | 0/14 | No |
N number of the study population, E+ positive expression, MA multivariate analysis, NA not applicable, TIS total immunostaining score, IHC immunohistochemistry